Calendario›INCY›Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)
Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)
Ensayo de INCYTE CORP en MPN (Myeloproliferative Neoplasms) (del registro, en inglés).
- Fase
- no aplica
- Estado
- Completado
- Participantes
- 2.544
- Centros
- 266
- Fin del objetivo primario
- ago 2019
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio observacional. Comenzó en jul 2014.
Qué mide
Description of patterns of the disease Polycythemia Vera (PV), and associations of such patterns with patients' exposures or treatments (Every 3 months for approximately 36 months) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis is a Phase IV, multicenter, non-interventional, non-randomized, prospective, observational study in an adult population (patients \>18 years old) of men and women who have been diagnosed with clinically overt PV and are being followed in either community or academic medical centers in the United States who will be enrolled over a 12-month period and observed for 36 months from the date the last patient is enrolled.
Más ensayos de INCY
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| tafasitamab · InMIND | Fase 3 | En marcha, sin reclutar | feb 2024 (real) |
| Tafasitamab · MINDway | Fase 1/2 | En marcha, sin reclutar | jul 2024 (real) |
| Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) | no aplica | Reclutando pacientes | jun 2025 (prevista, ya pasada: sin actualizar en el registro) |
| tafasitamab · J-MIND | Fase 1/2 | En marcha, sin reclutar | jul 2025 (real) |
| INCA034176 | Fase 3 | En marcha, sin reclutar | ago 2025 (real) |
| Povorcitinib | Fase 3 | En marcha, sin reclutar | feb 2026 (real) |
Todos los de INCY, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT02252159), actualizada en abr 2021.